Transcriptional correlates of the pathological phenotype in a Huntington’s disease mouse model

被引:0
|
作者
Andrea Gallardo-Orihuela
Irati Hervás-Corpión
Carmen Hierro-Bujalance
Daniel Sanchez-Sotano
Gema Jiménez-Gómez
Francisco Mora-López
Antonio Campos-Caro
Monica Garcia-Alloza
Luis M. Valor
机构
[1] Instituto de Investigación e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA),Área de Fisiología, Facultad de Medicina
[2] Unidad de Investigación,undefined
[3] Hospital Universitario Puerta del Mar,undefined
[4] Av. Ana de Viya 21,undefined
[5] Universidad de Cádiz,undefined
[6] Plaza Fragela,undefined
[7] Servicio de Inmunología,undefined
[8] Hospital Universitario Puerta del Mar,undefined
[9] Av. Ana de Viya 21,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Huntington disease (HD) is a fatal neurodegenerative disorder without a cure that is caused by an aberrant expansion of CAG repeats in exon 1 of the huntingtin (HTT) gene. Although a negative correlation between the number of CAG repeats and the age of disease onset is established, additional factors may contribute to the high heterogeneity of the complex manifestation of symptoms among patients. This variability is also observed in mouse models, even under controlled genetic and environmental conditions. To better understand this phenomenon, we analysed the R6/1 strain in search of potential correlates between pathological motor/cognitive phenotypical traits and transcriptional alterations. HD-related genes (e.g., Penk, Plk5, Itpka), despite being downregulated across the examined brain areas (the prefrontal cortex, striatum, hippocampus and cerebellum), exhibited tissue-specific correlations with particular phenotypical traits that were attributable to the contribution of the brain region to that trait (e.g., striatum and rotarod performance, cerebellum and feet clasping). Focusing on the striatum, we determined that the transcriptional dysregulation associated with HD was partially exacerbated in mice that showed poor overall phenotypical scores, especially in genes with relevant roles in striatal functioning (e.g., Pde10a, Drd1, Drd2, Ppp1r1b). However, we also observed transcripts associated with relatively better outcomes, such as Nfya (CCAAT-binding transcription factor NF-Y subunit A) plus others related to neuronal development, apoptosis and differentiation. In this study, we demonstrated that altered brain transcription can be related to the manifestation of HD-like symptoms in mouse models and that this can be extrapolated to the highly heterogeneous population of HD patients.
引用
收藏
相关论文
共 50 条
  • [21] Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease
    Gu, Xiaofeng
    Andre, Veronique M.
    Cepeda, Carlos
    Li, Shi-Hua
    Li, Xiao-Jiang
    Levine, Michael S.
    Yang, X. William
    MOLECULAR NEURODEGENERATION, 2007, 2 (1)
  • [22] Correlates of Apathy in Huntington's Disease
    van Duijn, E.
    Reedeker, N.
    Giltay, E. J.
    Roos, R. A. C.
    van der Mast, R. C.
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2010, 22 (03) : 287 - 294
  • [23] Cardiac Conduction Disease in Huntington's Disease Mouse Model (BACHD)
    Zhu, Yujie
    Shamblin, Isaac
    Ali, Sameen
    Gray, Michelle
    Huke, Sabine
    FASEB JOURNAL, 2018, 32 (01):
  • [24] Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease
    Fisher, Simon P.
    Black, Sarah W.
    Schwartz, Michael D.
    Wilk, Alan J.
    Chen, Tsui-Ming
    Lincoln, Webster U.
    Liu, Helen W.
    Kilduff, Thomas S.
    Morairty, Stephen R.
    BRAIN, 2013, 136 : 2159 - 2172
  • [25] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Chen, Xi
    Wu, Jun
    Lvovskaya, Svetlana
    Herndon, Emily
    Supnet, Charlene
    Bezprozvanny, Ilya
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [26] Brain pericyte response in a mouse model of Huntington's disease
    Padel, T.
    Ozen, I.
    Roth, M.
    Paul, G.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 479 - 479
  • [27] Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease
    Kumar, Ashish
    Kneynsberg, Andrew
    Tucholski, Janusz
    Perry, Giselle
    van Groen, Thomas
    Detloff, Peter J.
    Lesort, Mathieu
    EXPERIMENTAL NEUROLOGY, 2012, 237 (01) : 78 - 89
  • [28] Progressive neuronal atrophy in a mouse model of Huntington's disease
    Raza, A. S.
    Davies, S. W.
    JOURNAL OF ANATOMY, 2007, 210 (05) : 607 - 607
  • [29] Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
    Turmaine, M
    Raza, A
    Mahal, A
    Mangiarini, L
    Bates, GP
    Davies, SW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8093 - 8097
  • [30] Studies of a knock-in mouse model of Huntington's disease
    Hickey, MA
    Thomasian, SE
    Gruen, E
    Zeitlin, S
    Li, XJ
    Faull, KF
    Levine, MS
    Chesselet, MF
    MOVEMENT DISORDERS, 2003, 18 (09) : 1091 - 1091